Amgen (NASDAQ: AMGN) announced that its Phase 3 OASIZ 301 study evaluating dazodalibep in adults with moderate-to-severe systemic Sjögren's disease ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE